CCCC financials
C4 Therapeutics (CCCC) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
CCCC income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $35.95M | $27.97M | -$104.49M | -$104.99M | -1.27 |
| 2024 | $35.58M | $35.58M | -$119.61M | -$105.32M | -1.52 |
| 2023 | $20.76M | $13.02M | -$139.03M | -$132.49M | -2.67 |
| 2022 | $31.10M | $31.10M | -$129.53M | -$128.18M | -2.62 |
| 2021 | $45.78M | $45.78M | -$82.13M | -$83.89M | -1.82 |
| 2020 | $33.20M | -$45.24M | -$60.45M | -$66.33M | -1.54 |
- CCCC revenue was $35.95M in fiscal 2025, net income -$104.99M.
Updated 2026-11-07 11:54 UTC